BJMO - 2020, issue Special, october 2020
T. Muilwijk MD, Prof, dr. J.P. Redorta , Prof, dr. A. Zietman , Prof, dr. Y. Loriot
Non-muscle invasive bladder cancer (NMIBC) makes up about 75% of all bladder cancers. Unfortunately, the majority of patients with NMIBC will experience a disease recurrence and a substantial proportion of them (~20–25%) will progress to muscle-invasive disease. Patients with high-risk NMIBC represent a particularly challenging patient group that is confronted with an increased 5-year risk of recurrence (up to 80 %) and progression (up to 50 %).1 At BMUC 2020, an entire session was dedicated to the different treatment options for these patients: Dr. Tim Muilwijk (University Hospitals Leuven, Leuven, Belgium) discussed BCG therapy, Prof. Dr. Joan Palou Redorta (Fundació Puigvert, Barcelona, Spain) talked about the potential of early cytoreductive therapy, Prof. Dr. Anthony Zietman (Massachusetts General Hospital, Boston, USA) made a case for the use of radiotherapy in high-risk NMIBC patients and Prof. Dr. Yohann Loriot (Gustave Roussy Cancer Campus, Paris, France) provided an overview of the data generated with targeted therapy in this setting.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
